Drugs / Clostridium Botulinum Toxin Type A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT03517319 | Sep 2016 → May 2018 | stroke disorder | Seoul National University Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT02947815 Comparator | Oct 2016 → Jan 2018 | benign essential blepharospasm | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clostridium Botulinum Toxin Type A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02947815 ↗ |
| Route | Intramuscular | “will be injected to finger flexor muscles” NCT03517319 ↗ |